NCT02021110View on ClinicalTrials.gov

Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Polycystic Liver DiseasePolycystic Kidney, Autosomal Dominant
Interventions
DRUG

Ursodeoxycholic Acid

The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks

Trial Locations (3)

Unknown

Radboud University Medical Centre Nijmegen, Nijmegen

Academic Medical Centre Amsterdam, Amsterdam

Donostia University Hospital, Donostia / San Sebastian

All Listed Sponsors
collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

lead

Radboud University Medical Center

OTHER

NCT02021110 - Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease | Biotech Hunter | Biotech Hunter